US87164F1057
© Globe Newswire
12.12.2025
SNDX
LISTED
NASDAQ
Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
News Preview
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (revumenib) was named Best New Drug at the Scrip Awards 2025, held by Citeline. The Best New Drug Award recognizes excellence in pharmaceutical develo...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.12.2025
SNDX
LISTED
NASDAQ
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on December 1, 2025, the Company granted inducement awards to purchase up to 15,500 shares of common stock to one new employee under the Company's 2023 Induceme...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.12.2025
SNDX
LISTED
NASDAQ
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
News Preview
NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025,...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
03.11.2025
SNDX
LISTED
NASDAQ
Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025
News Preview
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, December 8, 2025, at 7:00 a.m. ET during the 67th American Society of H...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
03.11.2025
SNDX
LISTED
NASDAQ
Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025
News Preview
– 12 revumenib and 11 axatilimab abstracts accepted, including 6 oral presentations, underscoring Syndax’s leadership in menin inhibition and CSF-1R inhibition –...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.10.2025
SNDX
LISTED
NASDAQ
Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025
News Preview
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third quarter 2025 financial results and provide a business update on Monday, November 3, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2025
SNDX
LISTED
NASDAQ
Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
News Preview
– First and only therapy FDA approved in both R/R acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation –...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.10.2025
SNDX
LISTED
NASDAQ
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October 1, 2025 the Company granted inducement awards to purchase up to 138,900 shares of common stock to 10 new employees under the Company's 2023 Inducemen...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
SNDX
LISTED
NASDAQ
Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
News Preview
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia were updated to inclu...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.09.2025
SNDX
LISTED
NASDAQ
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
NEW YORK, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2025 the Company granted inducement awards to purchase up to 167,400 shares of common stock to 11 new employees under the Company's 2023 Induce...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.08.2025
SNDX
LISTED
NASDAQ
Syndax Announces Participation in September Investor Conferences
News Preview
NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.07.2025
SNDX
LISTED
NASDAQ
Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025
News Preview
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second quarter 2025 financial results and provide a business update on Monday, August 4, 2025....
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
12.06.2025
SNDX
LISTED
NASDAQ
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025
News Preview
– Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients –...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.06.2025
SNDX
LISTED
NASDAQ
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
News Preview
– 26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population –...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.05.2025
SNDX
LISTED
NASDAQ
Syndax Announces Participation in June Investor Conferences
News Preview
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conf...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.05.2025
SNDX
LISTED
NASDAQ
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)
News Preview
– Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r –...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.05.2025
SNDX
LISTED
NASDAQ
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on May 1, 2025 the Company granted inducement awards to purchase up to 188,100 shares of common stock to seven new employees under the Company's 2023 Inducement...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.04.2025
SNDX
LISTED
NASDAQ
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on April 1, 2025 the Company granted inducement awards to purchase up to 50,000 shares of common stock to four new employees under the Company'...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.03.2025
SNDX
LISTED
NASDAQ
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on March 1, 2025 the Company granted inducement awards to purchase up to 282,000 shares of common stock to 12 new employees under the Company's...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.03.2025
SNDX
LISTED
NASDAQ
Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
News Preview
– $7.7 million in Revuforj® (revumenib) net product revenue in initial five weeks of launch –...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.02.2025
SNDX
LISTED
NASDAQ
Syndax Announces Participation in March Investor Conferences
News Preview
WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.02.2025
SNDX
LISTED
NASDAQ
Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025
News Preview
WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its fourth quarter and full year 2024 financial results and provide a business update on Monday, March 3, 2025....
Themefolio
Profiler
Peergroup
© PR Newswire
04.02.2025
SNDX
LISTED
NASDAQ
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
WALTHAM, Mass., Feb. 4, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on February 1, 2025 the Company granted inducement awards to purchase up to 124,000 shares of common stock to six new employees under the Compa...
Themefolio
Profiler
Peergroup
© PR Newswire
15.01.2025
SNDX
LISTED
NASDAQ
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
News Preview
– U.S. launch expected in early February –
– Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drivers of inflammation and fibrosis –
– Pivotal data from the AGAVE-201 trial supporting FDA approval show treatment with Niktimvo resulted in durable responses across all organs studied and patient su...
Themefolio
Profiler
Peergroup
© PR Newswire
13.01.2025
SNDX
LISTED
NASDAQ
Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
– Launched Revuforj® (revumenib) for treatment of R/R acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older –
– Revumenib added to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)for AML and ALL –
– Niktimvo™ (axatilimab-csfr) approved by U.S. FDA for treatment of chronic GVHD after failure o...
Themefolio
Profiler
Peergroup
© PR Newswire
07.01.2025
SNDX
LISTED
NASDAQ
Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
News Preview
WALTHAM, Mass., Jan. 7, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14...
Themefolio
Profiler
Peergroup
© PR Newswire
03.01.2025
SNDX
LISTED
NASDAQ
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
WALTHAM, Mass., Jan. 3, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on January 1, 2025 the Company granted inducement awards to purchase up to 123,100 shares of common stock to five new employees under the Compa...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2024
SNDX
LISTED
NASDAQ
Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial
News Preview
– Subgroup analyses from Ph 2 protocol-defined R/R mNPM1 AML efficacy population (N=64) show responses across all major subgroups, including heavily pretreated patients –
– 26% CR+CRh (20/77) and 48% ORR (37/77) in all enrolled patients who met the efficacy evaluable criteria in Ph 2 R/R mNPM1 AML cohort –
– 100% ORR (37/37) and 95% CRc (35/37) i...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2024
SNDX
LISTED
NASDAQ
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
News Preview
– 82% ORR (27 of 33 pts) and 48% CR/CRh (16 of 33 pts) in SAVE trial studying revumenib in combination with venetoclax and decitabine/cedazuridine in R/R AML –
– 64% ORR (62 of 97 pts) and 23% CR/CRh (22 of 97 pts) with high rates of MRD negativity and ability to proceed to HSCT in expanded dataset of Ph 2 R/R KMT2Ar acute leukemia...
Themefolio
Profiler
Peergroup
© PR Newswire
03.12.2024
SNDX
LISTED
NASDAQ
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
WALTHAM, Mass., Dec. 3, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on December 1, 2024 the Company granted inducement awards to purchase up to 23,900 shares of common stock to two new employees under the Compan...
Themefolio
Profiler
Peergroup
© PR Newswire
27.11.2024
SNDX
LISTED
NASDAQ
Syndax Announces Participation at the Citi 2024 Global Healthcare Conference
News Preview
WALTHAM, Mass., Nov. 27, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a panel discussion on novel mechanisms in oncology at the Citi 2024...
Themefolio
Profiler
Peergroup
© PR Newswire
15.11.2024
SNDX
LISTED
NASDAQ
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
News Preview
– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation –
– Syndax to host conference call today at 6:00 p.m. ET –
WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX) today anno...
Themefolio
Profiler
Peergroup
© PR Newswire
12.11.2024
SNDX
LISTED
NASDAQ
Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
News Preview
– Primary endpoint met with CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R mNPM1 AML patients (p-value = 0.0014) –
– 47% (30/64) ORR in a heavily pre-treated population, including 75% with prior venetoclax exposure in the efficacy population –
– Favorable safety and tolerability profile; only 5% of patients discontinued due to tr...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2024
SNDX
LISTED
NASDAQ
Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update
News Preview
– New revumenib and Niktimvo™ clinical data will be highlighted at 66th ASH Annual Meeting –
– mNPM1 AML topline data from AUGMENT-101 expected in 4Q24; potential sNDA filing in 1H25 –
– Revumenib NDA in R/R KMT2Ar acute leukemia is being reviewed under RTOR; PDUFA action date of December 26, 2024 –
– Niktimvo approved by U.S. FDA for treatment...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2024
SNDX
LISTED
NASDAQ
Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024
News Preview
WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, December 9, 2024, at 7:00 a.m. PT/10:00 a.m. ET during...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2024
SNDX
LISTED
NASDAQ
Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting
News Preview
– New monotherapy and combination data in acute leukemia further highlight revumenib's compelling clinical profile –
– 64% ORR (62/97) in expanded dataset of patients with R/R KMT2Ar acute leukemia in Ph 2 AUGMENT-101 pivotal cohort –
– 88% ORR (23/26) in SAVE trial testing revumenib, venetoclax and decitabine/cedazuridine combination in R/R A...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2024
SNDX
LISTED
NASDAQ
Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting
News Preview
– Rapid responses and symptom improvement observed in inflammatory and fibrotic manifestations of chronic GVHD in heavily pretreated patients –
WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq:SNDX), today announced that multiple abstracts evaluating Niktimvo™ (axatilimab-csfr), an anti-CSF-1R antibody for the treatment...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2024
SNDX
LISTED
NASDAQ
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™
News Preview
Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenib
Expected to fund Company through profitability; proforma cash approaching $800 million as of June 30
WALTHAM, Mass. and NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX) and Royalty Pharma plc (Nasdaq:...
Themefolio
Profiler
Peergroup
© PR Newswire
01.11.2024
SNDX
LISTED
NASDAQ
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
WALTHAM, Mass., Nov. 1, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on November 1, 2024 the Company granted inducement awards to purchase up to 78,700 shares of common stock to four new employees under the Compa...
Themefolio
Profiler
Peergroup
© PR Newswire
01.11.2024
SNDX
LISTED
NASDAQ
Syndax Announces Participation in November Investor Conferences
News Preview
WALTHAM, Mass., Nov. 1, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upco...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2024
SNDX
LISTED
NASDAQ
Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024
News Preview
WALTHAM, Mass., Oct. 29, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its third quarter 2024 financial results and provide a business update on Tuesday, November 5, 2024.
In connection with the ea...
Themefolio
Profiler
Peergroup
© PR Newswire
04.10.2024
SNDX
LISTED
NASDAQ
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
WALTHAM, Mass., Oct. 4, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on October 1, 2024 the Company granted inducement awards to purchase up to 62,700 shares of common stock to five new employees under the Compan...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2024
SNDX
LISTED
NASDAQ
Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease
News Preview
– Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg every 2 weeks dose achieving a complete or partial response within the first six months of treatment –
– Niktimvo approved by U.S. FDA for the treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy i...
Themefolio
Profiler
Peergroup
© PR Newswire
06.09.2024
SNDX
LISTED
NASDAQ
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
WALTHAM, Mass., Sept. 6, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on September 1, 2024 the Company granted an inducement award to purchase up to 60,000 shares of common stock to one new employee under the Com...
Themefolio
Profiler
Peergroup
© PR Newswire
12.08.2024
SNDX
LISTED
NASDAQ
Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia
News Preview
– Pivotal AUGMENT-101 trial met its primary endpoint at interim analysis of patients with KMT2Ar AML and ALL (p-value = 0.0036) –
– NDA filing for revumenib in R/R KMT2Ar acute leukemia is being reviewed under RTOR; PDUFA action date of December 26, 2024 –
WALTHAM, Mass., Aug. 12, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clin...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
